{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T14:18:45Z","timestamp":1715955525521},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.diagmicrobio.2007.10.018","type":"journal-article","created":{"date-parts":[[2007,11,10]],"date-time":"2007-11-10T12:15:37Z","timestamp":1194696937000},"page":"467-472","source":"Crossref","is-referenced-by-count":10,"title":["Selection of a surrogate \u03b2-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem"],"prefix":"10.1016","volume":"59","author":[{"given":"Ronald N.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Janechek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/JCM.25.8.1570-1571.1987","article-title":"Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin","volume":"25","author":"Barry","year":"1987","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib2","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.49.9.3944-3947.2005","article-title":"Use of pharmacokinetic\u2013pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem","volume":"49","author":"Bhavnani","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/jac\/dki134","article-title":"Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control","volume":"55","author":"Brown","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib4","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1128\/AAC.49.6.2510-2511.2005","article-title":"In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis","volume":"49","author":"Chen","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib5","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved standard, M7-A7","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib6","series-title":"Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement; M100-S17","author":"Clinical and Laboratory Standards Institute","year":"2007"},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib26","unstructured":"Doribax\u2122 Product Package Insert (2007) Ortho-McNeil Pharmaceuticals, Inc., Raritan, NJ. Revised 10\/2007."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib7","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1469-0691.2005.01271.x","article-title":"Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)","volume":"11","author":"Fritsche","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib8","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1128\/AAC.48.4.1384-1396.2004","article-title":"In vitro antimicrobial activity of doripenem, a new carbapenem","volume":"48","author":"Ge","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.tox.2006.02.004","article-title":"Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with \u03b2-lactam antibiotics","volume":"222","author":"Horiuchi","year":"2006","journal-title":"Toxicology"},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.diagmicrobio.2006.01.019","article-title":"Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside","volume":"55","author":"Huynh","year":"2006","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0732-8893(01)00229-2","article-title":"Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997-99)","volume":"39","author":"Jones","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0732-8893(93)90041-5","article-title":"Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result","volume":"17","author":"Jones","year":"1993","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib11","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.48.8.3136-3140.2004","article-title":"Activities of doripenem (S-4661) against drug-resistant clinical pathogens","volume":"48","author":"Jones","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jac\/dkh298","article-title":"Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations","volume":"54","author":"Jones","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diagmicrobio.2004.12.008","article-title":"Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various lactamase resistance mechanisms","volume":"52","author":"Jones","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib15","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1128\/JCM.00576-06","article-title":"Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program","volume":"44","author":"Jones","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1128\/AAC.48.4.1313-1319.2004","article-title":"Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized \u03b2-lactamases","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib18","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.48.8.3086-3092.2004","article-title":"Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib19","series-title":"Development of In Vitro Susceptibility Testing Criteria and Quality Controls Parameters; Approved Guideline, M23-A2","author":"National Committee for Clinical Laboratory Standards","year":"2001"},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib20","doi-asserted-by":"crossref","first-page":"767","DOI":"10.5858\/2006-130-767-PAOAAA","article-title":"Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001\u20132003)","volume":"130","author":"Pfaller","year":"2006","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"Suppl 2","key":"10.1016\/j.diagmicrobio.2007.10.018_bib21","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1086\/504487","article-title":"Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"43","author":"Rice","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/ja.2006.31","article-title":"Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem","volume":"59","author":"Sakyo","year":"2006","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib23","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1128\/AAC.50.2.819-821.2006","article-title":"In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients","volume":"50","author":"Traczewski","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib24","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1128\/AAC.49.10.4413-4417.2005","article-title":"In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates","volume":"49","author":"Wexler","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.10.018_bib25","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889307005020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889307005020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T07:53:35Z","timestamp":1630050815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889307005020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0732889307005020"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2007.10.018","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}